Skip to main content
Professional Technical IVT

GLP-1 receptor agonist

Also written as: GLP-1 — glucagon-like peptide-1 receptor agonist

Injectable diabetes medications that provide significant cardiovascular protection through weight loss and direct cardiac benefits.

Full Definition

Glucagon-like peptide-1 receptor agonists are injectable medications that mimic the incretin hormone GLP-1, enhancing glucose-dependent insulin secretion and slowing gastric emptying. These agents promote substantial weight loss and have demonstrated cardiovascular benefits in high-risk patients, including reduced risk of major adverse cardiovascular events. They represent a cornerstone of modern cardiovascular prevention strategies, particularly in patients with diabetes and obesity.

Usage

Usage note: Hyphenate when used as a compound modifier; distinguish from GLP-2 agonists which have different therapeutic applications.

In Context

  • "The GLP-1 receptor agonist was initiated for both glycemic control and cardiovascular risk reduction." — Treatment plan documentation
  • "Weekly GLP-1 receptor agonists have shown superior cardiovascular outcomes compared to daily formulations in some trials." — Pharmaceutical review

Also known as

incretin mimetic GLP-1 agonist

Don't confuse with

GLP-2 agonist GIP receptor agonist SGLT2 inhibitor

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON